Printer Friendly

THERAGENICS ANNOUNCES SECOND QUARTER RESULTS

 ATLANTA, July 29 /PRNewswire/ -- Theragenics Corp. (NASDAQ: THRX), an Atlanta-based cancer therapy company, announced today that, for the second quarter ended June 30, 1993, it achieved a net profit of $193,000, or $.02 per share, compared to a net profit of $242,000, or $.02 per share before extraordinary items, compiled in the same quarter last year. After an extraordinary adjustment for tax loss carryforward, 1992 second quarter profit was $374,000, or $.03 per share.
 Theragenics' revenues for the second quarter of 1993 were $1,171,000, compared to $1,158,000 achieved during the same period last year.
 For the first six months ended June 30, 1993, before extraordinary credits and adjustments for changes in accounting practice, Theragenics had a net profit of $333,000, or $.03 per share, compared to a net profit of $562,000, or $.05 per share, for the first half of 1992. The company's net profit for the first half of 1993 was $3,193,000, or $.27 per share, compared to a net profit of $880,000, or $.08 per share, for the same period in 1992.
 The company's revenue for the first half of fiscal 1993 were $2,338,000, compared to the $2,362,000 in revenues compiled for the same period last year.
 President and CEO Chris Jacobs attributed the company's second quarter revenues, which were below forecast, primarily to "problems associated with a manufacturing changeover" which she said had "led to various production delays." Ms. Jacobs added that while most expenses remained in check, quarterly profit was adversely affected by increased depreciation expense associated with the company's new cyclotron and facility.
 "However," said the Theragenics president, "for the first time in our history, we obtained direct control of the production of our manufactured materials and also reduced dependence on outside vendors to an all-time low." Although she cautioned that concerns associated with the manufacturing changeovers could persist, she affirmed that problems facing the company were those the company "had solved in the past, are solving now, and will continue to solve in the future.
 "Our forecast, though delayed, reflects achievable, realistic numbers," she said. "This company has always gone for the stretch. This year is no different."
 Theragenics manufactures and markets TherSeed, a nonsurgical, outpatient treatment which uses implanted Palladium-103 seeds to eradicate prostate cancer.
 THERAGENICS CORP.
 Consolidated Statement of Operations
 (Unaudited)
 Three months ended June 30 1993 1992
 Revenues $1,171,000 $1,158,000
 Net profit before
 extraordinary items 193,000 242,000
 Extraordinary credit for
 tax loss carryforward -- 132,000
 Net profit after
 extraordinary items $ 193,000 $ 374,000
 Earnings per common share
 before extraordinary items $.02 $.02
 Extraordinary items -- .01
 Earnings per common share
 after extraordinary items $.02 $.03
 Weighted average shares 11,768,034 11,119,215
 Six months ended June 30 1993 1992
 Revenues $2,338,000 $2,362,000
 Net earnings before
 extraordinary items and
 changes in accounting
 principle 333,000 562,000
 Extraordinary credit for
 tax loss carryforward -- 318,000
 Cumulative effect on prior
 years of change in method
 of accounting for income
 taxes 2,860,000 --
 Net earnings after
 extraordinary items and
 changes in accounting
 principle $3,193,000 $ 880,000
 Earnings per common share
 before extraordinary items
 and changes in accounting
 principle $.03 $.05
 Extraordinary items -- .03
 Changes in accounting principle .24 --
 Earnings per common share after
 extraordinary items and changes
 in accounting principle $.27 $.08
 Weighted average shares 11,736,283 11,129,518
 -0- 7/29/93
 /CONTACT: Bruce W. Smith of Theragenics, 404-381-8338; or Rick Eisenberg of Eisenberg Communications, 212-496-6828, for Theragenics/
 (THRX)


CO: Theragenics Corp. ST: Georgia IN: MTC SU: ERN

GK-LG -- NY072 -- 7268 07/29/93 13:51 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 29, 1993
Words:617
Previous Article:BIRD CORPORATION DECLARES QUARTERLY DIVIDEND
Next Article:MEDICALCONTROL, INC., REPORTS EARNINGS; SECOND QUARTER NET 8 CENTS A SHARE VS. 6 CENTS A SHARE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters